Home / News

Hutchison MediPharma Wins First Chinese Syk Inhibitor Approval, and the First Oral wAIHA Drug Anywhe

Date:11-21-2026

China's drug regulator approved sovleplenib, an oral spleen tyrosine kinase inhibitor developed by Hutchison MediPharma, on 19 November 2026, for two autoimmune blood disorders at once: primary immune thrombocytopenia (ITP) and warm autoimmune haemolytic anaemia (wAIHA). It is the first Syk inhibitor cleared in China and the first oral targeted therapy approved anywhere for wAIHA.

Both conditions share a mechanism: antibodies coat the patient's own platelets or red cells, and macrophages in the spleen destroy them. Standard care has been corticosteroids, immunosuppressants and transfusions, all of which suppress broadly, work imperfectly and cause cumulative toxicity. Syk is the kinase through which B-cell and Fc receptors transmit the signal that drives both antibody production and macrophage engulfment, so blocking it interrupts the disease at two points rather than one.

Clinical results

  • ESLIM-01 (ITP): durable response rate 48.4% versus 0% on placebo
  • Overall response 68.3% at 0-12 weeks and 70.6% at 0-24 weeks
  • ESLIM-02 (wAIHA): met its primary endpoint, with a safety profile consistent with the ITP study
  • No thrombotic events observed in either trial — the key differentiator for a drug taken long term by patients already prone to clotting
  • Two FDA orphan drug designations granted in October 2026, for ITP and autoimmune haemolytic anaemia

Why the safety profile is the story

ITP and wAIHA patients are not a homogeneous group. Many have coexisting clotting risk, and the earlier generation of Syk and BTK inhibitors carried signals that made physicians careful about combining them with anticoagulation. A 48.4% durable response is respectable but not unprecedented; the absence of thrombotic events across two Phase III programmes is what makes the drug usable as chronic therapy rather than a bridge.

The wAIHA approval is the more unusual one. There was no approved targeted therapy for the condition in China, which means the trial had no active comparator and the regulatory pathway itself was being defined as the study ran. Being first in that indication is a genuine clinical claim rather than a marketing one.

What it means for the company

Sovleplenib is Hutchison MediPharma's fifth class 1 innovative drug and its first outside oncology. The company built its franchise on small-molecule kinase inhibitors in solid tumours, and moving that chemistry into immune regulation is a platform argument rather than a one-off. It is now one of five Chinese companies holding five or more self-developed class 1 drugs, and the only one in Shanghai.

Manufacturing sits at the company's Zhangjiang site, which passed an FDA inspection in January 2026 with no Form 483 observations and already produces five commercial products. That matters for the international path: orphan designations in the US are the first step, and a site with a clean FDA record is a prerequisite for filing.

What is not yet proven

No pricing has been announced, and reimbursement is the real gate in China — a drug that costs more than chronic corticosteroids without a clear quality-of-life argument will struggle outside tier-3 hospitals. Long-term extension data beyond 24 weeks is limited, and there is no head-to-head comparison against the thrombopoietin receptor agonists that dominate ITP treatment.

For wAIHA, the trial population was small by definition of a rare disease, and post-marketing surveillance will be the first real test of the thrombotic safety claim in older patients with cardiovascular comorbidity, a group usually under-represented in registration studies.

Source

Reported by Science and Technology Daily and PharmaCube, 19-20 November 2026. Chinese-language sources only; no English-language coverage of this approval was found at the time of writing.

Prev: Return to list

Next: AC311A Flies First Emergency Flotation Test by a Chinese Light Helicopter